Spectrum Pharmaceuticals Presents Poziotinib Data in Patients with Brain Metastases from the ZENITH20 Clinical Trial at 2021 ASCO Annual Meeting
“CNS metastases are a common and life-threatening complication of metastatic disease in NSCLC patients,” said
CNS Activity from the ZENITH20 Clinical Trial
The ZENITH20 trial has enrolled NSCLC patients with EGFR and HER2 exon 20 insertion mutations. This analysis looked at the results for 284 patients from Cohorts 1, 2 and 3. 36 patients had brain metastases as reviewed by an independent central imaging laboratory from baseline. Brain metastasis occurs frequently in NSCLC, up to 25% of patients, and is associated with short survival. Patients received poziotinib at a dose of 16mg once daily.
The poster presentations will be available for viewing by registered participants during the conference via the ASCO website beginning on
About
Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These forward-looking statements relate to a variety of matters, including, without limitation, statements that relate to Spectrum’s business and its future, including the significance of CNS activity in patients with NSCLC with EGFR or HER2 mutations; the ability to achieve a clinically meaningful effect for patients with brain metastases and the magnitude of that effect; the company’s ability to advance and fund the development and commercialization of its late-stage pipeline assets and such assets’ ability to serve areas of unmet need; and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Spectrum and are subject to significant risks and uncertainties that could cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. Risks that could cause actual results to differ include, but are not limited to, the possibility that the different methodologies, assumptions and applications the company utilizes to assess particular safety or efficacy parameters may yield different statistical results, and even if the company believes the data collected from the clinical trials of its product candidates, including poziotinib, are positive, these data may not be sufficient to support approval by the FDA; the possibility that success in early clinical trials, especially if based on a small patient sample, might not result in success in later clinical trials, and other unforeseen events during clinical trials which could cause delays or other adverse consequences; other uncertainties inherent in new product development; the possibility that Spectrum’s new and existing drug candidates, including poziotinib, may not ultimately prove to be safe or effective; the possibility that Spectrum’s new and existing drug candidates, if approved, may not be more effective, safer, or more cost efficient than competing drugs; and other risks that are described in further detail in the company's reports filed with the
© 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20210604005126/en/
Managing Director, Westwicke ICR
858.356.5932
robert.uhl@westwicke.com
Chief Financial Officer
949.788.6700
InvestorRelations@sppirx.com
Source: